



SDI Review Form 1.6

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	2014_JAMPS_12818
Title of the Manuscript:	The effects of silymarin on serum soluble apoptosis markers in β -thalassemia major patients receiving desferrioxamine
Type of the Article	Short Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	In Statistical analysis of Method part: Please correct the name of statistical test(non-parametric sample t test is incorrect)	We corrected statistical test(highlighted in the text)
	The significance level of p value should be mentioned in this part.	We added the significance level of p value (Highlighted text)
	Which type of randomization is used?	It's a double-blind, placebo controlled clinical trial. (highlighted text), Patients were randomized into a treatment group and a placebo group based on the date of their first visit after enrollment.
	In result: The authors have not compared the two groups of patients with regard to clinical and biological variables.	We compared clinical and biological variables of two group patients in ne w published paper by Moayedi et.al (2013) ref#4 in manuscript. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in b-thalassemia major patients receiving desferrioxamine.
	In table 2 P values should be mentioned.	P values were mentioned in table 2.
	Do the authors sure with regard to good compliance of patients in drug consumption in each group?	During the study period, no change was allowed in the dose of desferrioxamine. Compliance with Legalon_ was assessed by pill counts and diary cards that recorded the time and date of taking each pill. Patients received a new supply of capsules every month, and they returned all diary cards at the same time.
	In discussion part, ROS can be used and there is no need to rewrite the complete phrase. This is not for the first time.	We corrected it in discussion.
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		